---
title: "Jindal Drugs Pvt Ltd (JINDALDRUG) — Share Price, Financials & Analysis"
symbol: "JINDALDRUG"
company: "Jindal Drugs Pvt Ltd"
canonical: "https://tapetide.com/stocks/JINDALDRUG"
generated_at: "2026-10-13T10:59:42.266Z"
---

# Jindal Drugs Pvt Ltd (JINDALDRUG)

Canonical page: https://tapetide.com/stocks/JINDALDRUG

## Company

- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No

## Latest Price

## Key Insights

### Weaknesses

- The company has delivered a poor sales growth of -18.4% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
- Earnings include an other income of Rs.72.2 Cr.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -20% | 31% | 11% |
| revenue growth | -8% | -1% | -18% |

## Financial Statements

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 414 | 1101 | 955 | 940 | 866 | 311 | 319 | 400 | 340 | 314 |
| Expenses | 410 | 991 | 820 | 801 | 807 | 274 | 289 | 327 | 232 | 249 |
| Operating Profit | 5 | 110 | 135 | 138 | 59 | 37 | 30 | 73 | 108 | 65 |
| OPM % | 1.1 | 10 | 14 | 15 | 7 | 12 | 9 | 18 | 32 | 21 |
| Other Income | 33 | 25 | 38 | 19 | 38 | 31 | 36 | 131 | 52 | 72 |
| Interest | 2 | 36 | 11 | 20 | 6 | 4 | 2 | 3 | 2 | 5 |
| Depreciation | 9 | 11 | 15 | 18 | 25 | 16 | 17 | 16 | 14 | 13 |
| Profit before tax | 27 | 87 | 146 | 120 | 65 | 48 | 47 | 185 | 143 | 120 |
| Tax % | 22 | 19 | 21 | 21 | 20 | 15 | 14 | 22 | 22 | 25 |
| Net Profit | 21 | 71 | 116 | 95 | 52 | 41 | 41 | 145 | 111 | 90 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 474 | 545 | 661 | 757 | 809 | 948 | 848 | 993 | 1104 | 1194 |
| Borrowings | 97 | 108 | 152 | 155 | 143 | 158 | 8 | 120 | 44 | 196 |
| Other Liabilities | 26 | 43 | 95 | 71 | 64 | 94 | 147 | 155 | 156 | 153 |
| Total Liabilities | 609 | 707 | 920 | 995 | 1028 | 1212 | 1015 | 1280 | 1316 | 1555 |
| Fixed Assets | 94 | 107 | 162 | 171 | 253 | 238 | 162 | 148 | 135 | 124 |
| CWIP | 18 | 32 | 67 | 89 | 6 | 4 | 0 | 0 | 233 | 234 |
| Investments | 25 | 17 | 70 | 234 | 258 | 213 | 338 | 120 | 120 | 120 |
| Other Assets | 472 | 551 | 620 | 501 | 511 | 757 | 515 | 1012 | 828 | 1078 |
| Total Assets | 609 | 707 | 920 | 995 | 1028 | 1212 | 1015 | 1280 | 1316 | 1555 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | — | — | 120 | 65 | 129 | 201 | 139 | 138 | -9 |
| Cash from Investing Activity | — | — | — | 0 | -128 | 52 | 50 | -355 | -71 | -178 |
| Cash from Financing Activity | — | — | — | 0 | 0 | 11 | -148 | 110 | -78 | 147 |
| Net Cash Flow | — | — | — | 120 | -63 | 191 | 104 | -107 | -10 | -39 |
| Free Cash Flow | — | — | — | 120 | 65 | 117 | 196 | 135 | 134 | -9 |
| CFO/OP | — | — | — | 87 | 110 | 430 | 742 | 245 | 160 | 43 |

### Ratios

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 80 | 50 | 72 | 37 | 43 | 177 | 70 | 80 | 34 | 56 |
| Inventory Days | 28 | 26 | 41 | 67 | 96 | 199 | 74 | 122 | 158 | 192 |
| Days Payable | 6 | 5 | 24 | 16 | 7 | 20 | 7 | 13 | 17 | 11 |
| Cash Conversion Cycle | 102 | 71 | 88 | 88 | 131 | 356 | 137 | 189 | 175 | 238 |
| Working Capital Days | 190 | 92 | 110 | 57 | 99 | 210 | 123 | 105 | 20 | -64 |
| ROCE % | 5 | 20 | 21 | 16 | 8 | 4 | 5 | 17 | 13 | 10 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 5 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 31.56 | Sell |
| EMA (10) | 31.44 | Sell |
| SMA (20) | 34.02 | Sell |
| EMA (20) | 32.68 | Sell |
| SMA (50) | 34.88 | Sell |
| EMA (50) | 35.89 | Sell |
| SMA (100) | 43.15 | Sell |
| EMA (100) | 38.34 | Sell |
| SMA (200) | 39.02 | Sell |
| EMA (200) | 35.55 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.1 | Neutral |
| MACD (12,26,9) | -1.54 | Sell |
| Stochastic (14,3,3) | 6.47 | Buy |
| ADX (14) | 22.87 | Neutral |
| Williams %R (14) | -83.74 | Buy |
| ATR (14) | 2.25 | High Volatility |
| ROC (12) | -19.08 | Sell |
| Stoch RSI (14) | 25.82 | Neutral |
| UO (7,14,28) | 34.06 | Neutral |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-10-13T10:59:42.266Z.